Healthcare Services

Global Acute Agitation And Aggression Treatment Market Global Report 2026 Market Report 2026–2035 Highlighting Expansion Outlook and Forecast Opportunities

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Acute Agitation And Aggression Treatment Market Evolve From 2026 To 2030?

The acute agitation and aggression treatment market size has demonstrated robust growth in recent years. It is anticipated to expand from $6.05 billion in 2025 to $6.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.2%. The historical expansion of this market stems from factors such as increasing prevalence of psychiatric disorders, rising emergency department visits for agitation, wider availability of antipsychotic medications, expansion of mental health services, and growing awareness of behavioral health conditions.

The acute agitation and aggression treatment market size is projected for significant expansion in the coming years, with an expectation to reach $8.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period can be attributed to the increasing demand for fast-acting therapeutic options, growing investments in neuropsychiatric drug development, the rising use of digital mental health tools, the expansion of integrated behavioral care models, and a heightened focus on patient-centric treatment pathways. Moreover, key trends anticipated in this period include the increasing adoption of rapid-acting pharmacologic treatments, a rising emphasis on personalized psychiatry approaches, the growing integration of digital monitoring tools, the broadening of emergency behavioral care protocols, and an enhanced focus on patient safety.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Acute Agitation And Aggression Treatment Market?

The rising occurrence of dementia is projected to fuel the expansion of the acute agitation and aggression treatment market in the future. Dementia describes a group of conditions marked by compromised memory, cognitive function, and the ability to perform daily activities. Agitation is a common symptom among individuals with dementia, typically manifesting as behaviors like restlessness, repetitive movements, or frequent hand gestures. Treating acute agitation and aggression is crucial in the context of dementia, as it helps lower the likelihood of detrimental symptoms, enhances the quality of life for patients, and addresses the root cause of their agitation. For example, data from February 2023, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that approximately 401,300 Australians were estimated to have dementia in 2022. This number is expected to double, reaching 849,300 by 2058. Consequently, the rising prevalence of dementia is propelling the growth of the acute agitation and aggression treatment market.

Which Segment Areas Are Covered In The Acute Agitation And Aggression Treatment Market Analysis?

The acute agitation and aggression treatment market covered in this report is segmented –

1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches

2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes

3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations

4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications

5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users

Subsegments:

1) By Behavioral Approaches: Cognitive Behavioral Therapy (CBT), De-escalation Techniques, Psychoeducation, Relaxation Therapy, Other Behavioral Interventions

2) By Environmental Interventions: Sensory Modifications, Safe Room Or Containment Strategies, Environmental Noise Reduction, Lighting And Temperature Adjustments, Other Environmental Interventions

3) By Pharmacologic Approaches: Antipsychotic Medications, Benzodiazepine Medications, Mood Stabilizers, Other Pharmacologic Agents, Adjunctive Medications

What Key Developments And Trends Are Impacting The Acute Agitation And Aggression Treatment Market?

Companies operating within the acute agitation and aggression treatment market are prioritizing the development of innovative products, such as a generic form of Zyprexa, to meet patient needs. Generic Zyprexa represents a variant of the brand-name drug Zyprexa, which incorporates olanzapine as its active ingredient and is employed in the management of psychotic conditions. For instance, in September 2023, Camber Pharmaceuticals, a pharmaceutical company situated in the US, launched a generic version of Zyprexa. This atypical antipsychotic medication is prescribed for addressing acute agitation associated with schizophrenia and bipolar I mania.

Which Global Companies Are Actively Competing In The Acute Agitation And Aggression Treatment Market?

Major companies operating in the acute agitation and aggression treatment market are Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

Read the full acute agitation and aggression treatment market report here:

https://www.thebusinessresearchcompany.com/report/acute-agitation-and-aggression-treatment-global-market-report

What Are The Leading Geographic Regions In The Acute Agitation And Aggression Treatment Market?

North America was the largest region in the acute agitation and aggression treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute agitation and aggression treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acute Agitation And Aggression Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13078&type=smp

Browse Through More Reports Similar to the Global Acute Agitation And Aggression Treatment Market 2026, By The Business Research Company

telepsychiatry global market report

https://www.thebusinessresearchcompany.com/report/telepsychiatry-global-market-report

psychedelic drugs global market report

https://www.thebusinessresearchcompany.com/report/psychedelic-drugs-global-market-report

neurodegenerative disorder therapeutic global market report

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795